IPFsym™, a platform to support the development of effective treatments for IPF patients
Patients with idiopathic pulmonary fibrosis (IPF) have a low survival prognosis and limited treatment options. Underlying its clinical presentation is a complex pathophysiology.
A substantial effort is being applied across the pharmaceutical and biotechnology industries to develop treatments for IPF, but the complexity of the mechanistic pathophysiology makes it challenging.
Join DILIsym Services Chief Scientific Officer, Scott Q Siler, who will describe the features and use of IPFsym v1A to support the development of effective treatments for IPF patients.